Compare BridgeBio Pharma Inc (BBIO) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Dicks Sporting Goods Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.34% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DKS | |
|---|---|---|
Market Cap | $16.61B | $19.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $239.17 |
52-Week Low | $47.29 | $187.78 |
Enterprise Value | $18.16B | $25.95B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.
The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
